TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04570124

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home Blood Pressure Telemonitoring
Description: Women will complete a 9-question survey (pre-education) prior to discharge and will go over an education video a study team member. Once discharged, women will be asked to measure their blood pressure daily for the first postpartum week, and then weekly until postpartum week 6. Women who have a doctor's visit scheduled during the first 10 days, a member of the study team will meet them there to assess blood pressure and answer any questions. Women who do not have a visit scheduled they will have a telehealth visit during days 8-10 to complete the same assessments. At the final visit, participants will measure their blood pressure via HBPT, prior to returning the unit, complete a post-education questionnaire, a post-study questionnaire and have any questions or concerns addressed.
Study: NCT04342858

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride Varnish
Description: Duraphat varnish®, Colgate-Palmolive (UK) Ltd., Guildford, Surrey, UK

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoride Varnish with tricalcium phosphate
Description: Clinpro white varnishTM, 3M ESPE, St Paul, MN, USA

Intervention type: OTHER
Group type: OTHER
Intervention: Oral health education
Description: Standard oral hygiene instructions every 3 months
Study: NCT02331667

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-seafood
Description: The aim is to investigate the effect of meals consisting of meat on learning abilities by using a two-armed individually randomized non-blinded intervention trial.
Study: NCT03840954

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation
Description: The application of NMES will be performed with the patient positioned in the supine position in the bed. Self-adhesive electrodes will be positioned at the motor points of the quadriceps and anterior tibial muscles respectively. A symmetrical biphasic pulsed current with a frequency of 80 Hz, a pulse width of 500 μs and an intensity at the motor threshold will be applied up to the maximum tolerated by the patient. ON and OFF time and total session time will be used according to protocol with progressive increase of the total intervention time and reduction of OFF time of the NMES. The device used will be the Neurodyn II model, manufactured by IBRAMED.~Patients will receive NMES for as long as they remain hospitalized or for up to 3 weeks.
Study: NCT01958359

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short IVR
Description: IVR-based alcohol diary with feedback

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic IVR
Description: IVR-based conversation offering a menu of exercises and vignettes.
Study: NCT00950248

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Idebenone
Description: idebenone, lactose monohydrate, microcrystalline cellulose, croscarmellose sodium povidone, magnesium stearate, silicon dioxide, film-coat: Opadry II 85F23495 (consisting of: aluminium lake, FD\&C yellow #6, macrogol/PEG 3550, polyvinylalcohol, titanium dioxide, talc)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: lactose monohydrate, microcrystalline cellulose, magnesium stearate, film-coat: Opadry II 85F23495 (consisting of: aluminium lake, FD\&C yellow #6, macrogol/PEG 3550, polyvinylalcohol, titanium dioxide, talc)
Study: NCT03218176

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Proximal single upper limb
Description: Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proximal staggered upper limb
Description: Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Distal single upper limb
Description: Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Distal staggered upper limb
Description: Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
Study: NCT03162835

Intervention type: OTHER
Intervention: Pain Neuroscience Education
Description: Children as well as their parents will receive a +/- 1h one-on-one educational session about the neurophysiology of pain, adjusted to the child's comprehension status. Parents will be present in the PNE session too. The PNE program for children contains two sections: (1) The healthy pain system and its function, divided in subsections each consisting of a specific neurophysiological pain concept (i.e. central nervous system anatomy, nociception and nociceptive pathways, up- and down-regulation of the nervous system) and (2) adaptations of the pain system following persistent pain. To ensure interaction between therapist and child, an interactive board game was developed and used throughout the full educational session.
Study: NCT00540800

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: given in combination with epirubicin or capecitabine
Study: NCT03218176

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Proximal single lower limb
Description: Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proximal staggered lower limb
Description: Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Distal single lower limb
Description: Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Distal staggered lower limb
Description: Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
Study: NCT00930878

Intervention type: DEVICE
Intervention: Cardiac Stenting
Description: Drug Eluting stent

Intervention type: DEVICE
Intervention: Cardiac Stenting
Description: Drug Eluting stent

Intervention type: DEVICE
Intervention: Cardiac Stenting
Description: Drug Eluting stent
Study: NCT03064971

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Standard of care provided by QuitlineNC includes Quit Coaches, counseling calls, nicotine replacement therapy, and written materials

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard of care provided by QuitlineNC includes Quit Coaches, counseling calls, nicotine replacement therapy, and written materials

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard of care provided by QuitlineNC includes Quit Coaches, counseling calls, nicotine replacement therapy, and written materials

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: smoking cessation DVD
Description: The evidence-based How to Quit DVD contains 60 minutes of smoking cessation information and strategies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PTF DVD
Description: Culturally specific smoking cessation DVD. This DVD contains 60 minutes of material.
Study: NCT03611673

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smell Test
Description: Oils are used for each of the different scents. Each scent will be put on an aromatherapy inhaling stick.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smell Test
Description: Oils are used for each of the different scents. Each scent will be put on an aromatherapy inhaling stick.
Study: NCT01890564

Intervention type: OTHER
Intervention: Pressure controlled ventilation
Description: For pressure controlled ventilation, the peak inflating pressure (PIP) is set for each tidal breath.

Intervention type: OTHER
Intervention: Volume controlled ventilation
Description: For volume controlled ventilation, the tidal volume is set.

Intervention type: OTHER
Intervention: PRVC ventilation
Description: Pressure-regulated, volume-controlled (PRVC) is an auto-regulated pressure-controlled mode of mechanical ventilation with a user-selected tidal volume target.
Study: NCT00540800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: given in combination with epirubicin or capecitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epirubicin
Description: for patients with locally advanced breast cancer, or metastatic breast cancer not previously treated with anthracyclines

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin
Description: for patients with locally advanced breast cancer, or metastatic breast cancer not previously treated with anthracyclines

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: for metastatic breast cancer patients previously treated with anthracyclines

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: for metastatic breast cancer patients previously treated with anthracyclines
Study: NCT04532775

Intervention type: DRUG
Group type: OTHER
Intervention: magnesium
Description: Preservative free magnesium which was used in the study was prepared in McGuff Pharmaceuticals, Inc. Laboratories and supplied in 50 ml vials containing magnesium (200 mg/ml).
Study: NCT02892318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 840 mg administered by IV infusion on Days 8 and 22 of each 28-day cycle.
Study: NCT04532775

Intervention type: DRUG
Group type: OTHER
Intervention: Methylprednisolone
Description: Methylprednisolone which was used in this study was supplied from E.I.P.I.C.O pharmaceuticals -Egypt under license of UPJOHN s.a Puurs-Belgium (Depo-Medrol).

Intervention type: DRUG
Group type: OTHER
Intervention: Methylprednisolone
Description: Methylprednisolone which was used in this study was supplied from E.I.P.I.C.O pharmaceuticals -Egypt under license of UPJOHN s.a Puurs-Belgium (Depo-Medrol).

Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacaine Hydrochloride
Description: local anesthetic drug

Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacaine Hydrochloride
Description: local anesthetic drug

Intervention type: DRUG
Group type: OTHER
Intervention: saline 0.9%
Description: solution for intravenous and epidural injection
Study: NCT03658447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg Pembrolizumab given 3 weekly for upto 35 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA
Description: 6-weekly 177Lu-PSMA treatments for upto 6 cycles starting at 8.5GBq with administered radioactivity reduced by 0.5GBq for each cycle.
Study: NCT02485704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: spinosad topical suspension, 0.9%
Description: Topically apply 0.9% suspension up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is the same as the drug minus the active ingredient spinosad (vehicle). Topically apply up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.
Study: NCT00931775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pindolol
Description: Pill orally administered. 15 mg/day t.i.d.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pindolol
Description: Pill orally administered. 15 mg/day t.i.d.
Study: NCT01770288

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anaerobic wingate test
Study: NCT01299922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine +mycophenolic acid+prednison
Description: Cyclosporine for 26 weeks Prednisone+mycophenolic acid 106 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolic Acid + prednison
Description: Mycophenolic Acid + prednison for 106 weeks
Study: NCT00302133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone hydrochloride
Description: Naltrexone hydrochloride 50 mg capsule daily for 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo arm
Study: NCT00545857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone
Description: Pioglitazone daily; dose varies with size

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pioglitazone
Description: Pioglitazone daily; dose varies with size

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo control
Description: Comparison of pioglitazone vs. placebo on the outcome of type 1 diabetes mellitus

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Comparison of pioglitazone vs. placebo on the outcome of type 1 diabetes mellitus
Study: NCT06167018

Intervention type: BEHAVIORAL
Intervention: Gut-directed hypnotherapy
Description: Gut-directed hypnotherapy for patients with irritable bowel syndrome (IBS). Gut-directed hypnotherapy (8-12 sessions), were given either in an individual manner or in a group setting.The hypnosis treatment is administered by two nurses specially trained in Cognitive Behavioral Therapy (CBT) and hypnotherapy. The treatment was based on the North Carolina protocol. Patients assessed gastro-intestinal symptom severity before, during and after treatment, as well as at follow-up.
Study: NCT01852266

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV cps2 Vaccine
Description: 10\^5.3 plaque forming units (PFUs) of RSV cps2 vaccine will be administered as nose drops (0.25 mL per nostril, for a total of 0.5 mL).
Study: NCT02224261

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy protocol
Description: Physical therapy protocol includes manual lymph-drainage technique in axilla, and proximal ipsilateral arm, specific thumb manual lymph-drainage on the taut cords to make them gradually more flexible, in conjunction with progressive active and action-assisted arm exercises stretching cords, and patient education.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Control protocol includes standard progressive active and action-assisted arm exercises \& patient education.
Study: NCT03740724

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: FCX-013
Description: FCX-013 is a genetically modified cell product obtained from the subject's own skin cells (autologous fibroblasts). The cells are expanded and genetically modified to express metalloproteinase-1 (MMP-1) under the control of a RheoSwitch (RTS®) system. FCX-013 cell suspension is injected intradermally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: veledimex
Description: Veledimex, is a small molecule which activates the RTS to induce expression of MMP-1 and is and provided as a liquid filled gelatin capsule for oral administration
Study: NCT04954560

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: losartan and eprosartan
Description: . Each study drug was given in a random order as a single morning dose (50 mg of losartan or 600 mg of eprosartan) for two periods each lasting 3 months separated by 2-week wash-out time.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: losartan and eprosartan
Description: . Each study drug was given in a random order as a single morning dose (50 mg of losartan or 600 mg of eprosartan) for two periods each lasting 3 months separated by 2-week wash-out time.
Study: NCT01967992

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: Low Carbohydrate, Ketogenic Diet

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: American Diabetes Association Diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness and Positive Affect Skills
Study: NCT01108588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (to match Aspirin)
Description: Placebo grossly matched Aspirin 300 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (to match Aspirin)
Description: Placebo grossly matched Aspirin 300 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (to match Aspirin)
Description: Placebo grossly matched Aspirin 300 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (to match Aspirin)
Description: Placebo grossly matched Aspirin 300 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (to match Aspirin)
Description: Placebo grossly matched Aspirin 300 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (to match Aspirin)
Description: Placebo grossly matched Aspirin 300 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin 300 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin 300 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin 300 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin 300 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin 300 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin 300 mg daily
Study: NCT01003652

Intervention type: PROCEDURE
Intervention: thyroidectomy
Description: Comparison between two groups of patients. One group is operated on using harmonic Focus for haemostasis compared to a second group of patients operated on with the conventional haemostasis using tie-and-clamp technique
Study: NCT00576225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-2103/carboplatin
Description: CT-2103 (175 mg/m2 10 min IV infusion) and carboplatin (AUC 6, 30 min IV infusion) on day 1 of each 21-day cycle for up to 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel/carboplatin
Description: Paclitaxel (175 mg/m2, 3 hr IV infusion) and carboplatin (AUC 6) (30 minute IV infusion) on day 1 of each 21-day cycle for up to 6 cycles.
Study: NCT03698123

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Modification
Description: Participants will be provided with meals, snacks and drinks with specific macronutrient compositions and encouraged to only eat and drink study meals, snacks and drinks and to avoid eating after 10:00 hours.
Study: NCT02892318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 840 mg administered by IV infusion on Days 8 and 22 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 840 mg administered by IV infusion on Days 8 and 22 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 840 mg administered by IV infusion on Days 8 and 22 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guadecitabine
Description: Guadecitabine 60 mg/m\^2 SC on Days 1-5 of every 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guadecitabine
Description: Guadecitabine 60 mg/m\^2 SC on Days 1-5 of every 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guadecitabine
Description: Guadecitabine 60 mg/m\^2 SC on Days 1-5 of every 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guadecitabine
Description: Guadecitabine 60 mg/m\^2 SC on Days 1-5 of every 28-day cycle.
Study: NCT02413645

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: TriMix_100
Description: 100 μg of TriMix in
Study: NCT01108588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel 75 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel 75 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel 75 mg daily
Study: NCT02413645

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: TriMix_300
Description: 300 μg of TriMix in

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 600μg mRNA (300 μg HIV mRNA+300 μg TriMix mRNA)
Description: 600 μg of mRNA (300 μg TriMix + 300 μg HIVACAT)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 900μg mRNA (600 μg HIV mRNA+300 μg TriMix mRNA)
Description: 900 μg of mRNA (300 μg TriMix + 600 μg HIVACAT)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1200μg mRNA (900 μg HIV mRNA+300 μg TriMix mRNA)
Description: 1200 μg of mRNA (300 μg TriMix + 900 μg HIVACAT)
Study: NCT01330953

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intravenous placebo dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2928057
Description: Single intravenous dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2928057
Description: Single intravenous dose.
Study: NCT00136227

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: small media intervention using video, flip chart, and pamphlets and a tailored interactive multimedia intervention
Study: NCT01330953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2928057
Description: Single intravenous dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2928057
Description: Single intravenous dose.
Study: NCT04400045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treosulfan
Description: Treosulfan 21mg/m2 (days -6, -5, -4)
Study: NCT02753075

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental Oral Rinse 1
Description: Oral rinse containing 1.5% w/w KOX, 0ppm F, pH 4.5

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental Oral Rinse 2
Description: Oral rinse containing 2.0% w/w KOX, 45ppm F, pH 4.5
Study: NCT01852266

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vaccine
Description: Placebo vaccine will be administered as nose drops (0.25 mL per nostril, for a total of 0.5 mL).
Study: NCT03468881

Intervention type: OTHER
Intervention: Communication Skills Training Package (KEW)
Description: A training package (called KEW: Know, Encourage and Warm-up) for therapeutic radiographers to manage emotional talk with breast cancer patients in treatment.
Study: NCT00153400

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Lifestyle Intervention
Description: Three face-to-face counseling sessions for nutrition and physical activity. Used a Spanish culturally tailored materials. These interventions were delivered by community health workers (CHWs) who are trained.